NICE type 2 diabetes guideline
This updated summary provides recommendations on blood glucose targets, and includes a useful algorithm on blood glucose management
NICE type 2 diabetes prevention guideline
This Guidelines summary covers the identification of people at high risk of type 2 diabetes and the provision of interventions for them
BSPID gum disease and diabetes guideline
A short overview of periodontal (gum disease) and its links with diabetes, including advice for community pharmacy teams
![20210603 Guidelines comparison table [online]](https://d3j7puhwqgd8ts.cloudfront.net/Pictures/100x67/0/0/0/10000_20210603guidelinescomparisontableonline_766677.png)
Type 2 diabetes pharmacological management pathway comparison
This comparison table summarises recommendations on the management of hyperglycaemia in adults with type 2 diabetes from ADA/EASD, NICE, and SIGN
Guideline for the managed introduction of biosimilar basal insulin
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Mylan.
SIGN type 2 diabetes guideline
This summary provides key recommendations on lifestyle management, treatment options, diabetic CVD, and CKD. Includes a useful treatment algorithm
Resource hub
Educational resources
Best practice treatment and management of patients with type 2 diabetes, cardiovascular disease, and heart failure
This management algorithm was developed by a multidisciplinary expert panel: Javaid et al with the support of an educational grant from AstraZeneca. Information intended for UK healthcare professionals.
Managing patients with non-valvular atrial fibrillation (NVAF) and diabetes—a patient case study
This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto▼(rivaroxaban)
PP-XAR-GB-2416 March 2022
Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd.
Guideline for the managed introduction of biosimilar basal insulin
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Mylan.
Pancreatic exocrine insufficiency guideline
This management algorithm was developed by a multidisciplinary expert panel: Hambling C et al with the support of a grant from Mylan Ltd.